PatientsVille.com Logo

PatientsVille

Daivobet Side Effects

Common Daivobet Side Effects


The most commonly reported Daivobet side effects (click to view or check a box to report):

Psoriasis (8)
Overdose (5)
Pustular Psoriasis (4)
Cushing's Syndrome (4)
Condition Aggravated (4)
Local Swelling (4)
Erythema (4)
Abortion Induced (3)
Skin Striae (3)
Adrenal Insufficiency (3)
Rebound Effect (3)
Dyspnoea (3)
Arthralgia (3)
Pyrexia (3)
Off Label Use (3)
Hyperhidrosis (2)
Erythrodermic Psoriasis (2)
Abasia (2)
Bone Pain (2)
Cataract (2)

➢ More



If you or someone in your family has experienced a serious side effect to a health product, you are encouraged to report the experience to your health care professional (e.g. physician, pharmacist). You could also complete a copy of the side effect reporting form or report your side effect to FDA.

Side effects reports are analyzed to discover potential health product safety signals. Some important reactions may take an extremely long time to develop or occur infrequently. Continued monitoring of adverse reactions is thus essential to maintain a comprehensive safety and effectiveness profile of health products.

Daivobet Side Effects Reported to FDA

The following Daivobet reports list potential signals of serious risks and new safety information that were identified using the FDA Adverse Event Reporting System (FAERS).
FAERS is a database that contains information on adverse event and medication errors reports submitted to FDA by healthcare professionals (such as physicians, pharmacists, nurses and others), consumers (such as patients, family members, layers and others) and manufacturers.


The appearance of Daivobet on this list does not mean that FDA has concluded that the drug has the listed risk. It means that FDA has identified a potential safety issue, but it does not mean that FDA has found a causal relationship between the drug and the listed risk.
Agranulocytosis
This is a report of a 90-year-old male patient (weight: NA) from FR, suffering from the following symptoms/conditions: NA, who was treated with Daivobet (dosage: NA, start time: Nov 27, 2013), combined with:
  • Omeprazole (omeprazole)
  • Oxybutinine
  • Diprosone
  • Aerius (desloratadine)
  • Omexel
  • Azithromycine Anhydre
  • Amlor (amlodipine Besilate)
  • Kardegic (acetylsalicylate Lysine)
and developed a serious reaction and side effect(s). The consumer presented with:
  • Agranulocytosis
which developed after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Daivobet treatment in male patients, resulting in agranulocytosis side effect.

Application Site Inflammation, Application Site Pruritus
This report suggests a potential Daivobet Application Site Inflammation, Application Site Pruritus side effect(s) that can have serious consequences. A 39-year-old female patient (weight: NA) from FR was diagnosed with the following symptoms/conditions: dermatitis atopic and used Daivobet (dosage: NA) starting 201308. Soon after starting Daivobet the patient began experiencing various side effects, including:
  • Application Site Inflammation
  • Application Site Pruritus
Drugs used concurrently: NA. Although Daivobet demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as application site inflammation, may still occur.

Premature Delivery, Exposure During Pregnancy
This Premature Delivery, Exposure During Pregnancy problem was reported by a consumer or non-health professional from FR. A 31-year-old female patient (weight: NA) was diagnosed with the following symptoms/conditions: NA. On NS this consumer started treatment with Daivobet Ointment (daivobet) (dosage: NA). The following drugs were being taken at the same time: NA. When commencing Daivobet Ointment (daivobet), the patient experienced the following unwanted symptoms/side effects:
  • Premature Delivery
  • Exposure During Pregnancy
The patient was hospitalized.Although all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as premature delivery, may become evident only after a product is in use by the general population.

Pustular Psoriasis, Inflammation, Rebound Psoriasis
This is a report of a 50-year-old male patient (weight: NA) from GB. The patient developed the following symptoms/conditions: psoriasis and was treated with Daivobet (dosage: NA) starting 2003. Concurrently used drugs: NA.Soon after that, the consumer experienced the following side effects:
  • Pustular Psoriasis
  • Inflammation
  • Rebound Psoriasis
This opens a possibility that Daivobet treatment could cause the above reactions, including pustular psoriasis, and some male subjects may be more susceptible.


Folliculitis, Abasia
A 31-year-old female patient (weight: NA) from FR with the following symptoms/conditions: psoriasis started Daivobet treatment (dosage: NA) on Mar 14, 2013. Soon after starting Daivobet treatment, the subject experienced various side effects, including:
  • Folliculitis
  • Abasia
Concurrently used drugs: NA. This finding indicates that some female patients could be more vulnerable to Daivobet.

Application Site Discolouration
A 46-year-old female patient from ES (weight: NA) experienced symptoms, such as: psoriasis and was treated with Daivobet Gel (daivobet /01643401/) (gel)(dosage: Very Little Amount In Each Plaque Of Psoriasis (once In 3-4 Days (9 Days)), Topical). The treatment was initiated on 201204. After that a consumer reported the following side effect(s):
  • Application Site Discolouration
Concurrently used drugs, which potentially could have contributed to side effect(s) or affected Daivobet Gel (daivobet /01643401/) (gel) efficacy:
  • Methotrexate (methotrexate)
  • Lederfolin 15 Mg Comprimidos, 10 Comprimidos (calcium Folinate) (tablet)


Eyelid Oedema, Sense Of Oppression, Nausea, Dyspnoea, Pharyngeal Oedema, Hypersensitivity
In this report, Daivobet was administered for the following condition: nail psoriasis.A 50-year-old female consumer from DE (weight: NA) started Daivobet treatment (dosage: On The Head) on Oct 30, 2012.Sometime after starting the treatment, the patient complained of the following side effect(s):
  • Eyelid Oedema
  • Sense Of Oppression
  • Nausea
  • Dyspnoea
  • Pharyngeal Oedema
  • Hypersensitivity
A possible interaction with other drugs could have contributed to this reaction: NA.Establishing a causal relationship between a specific drug and consumer's side effects is complex, but it is possible that in this report Daivobet treatment could be related to the listed above side effect(s).

Cataract
This is a report of the following Daivobet side effect(s):
  • Cataract
A 50-year-old male patient from FI (weight: NA) presented with the following condition: psoriasis and received a treatment with Daivobet (dosage: NA) starting: 2007.The following concurrently used drugs could have generated interactions: NA.This report suggests that a Daivobet treatment could be associated with the listed above side effect(s).

Pyrexia, Dermatitis Exfoliative
This Daivobet report was submitted by a 59-year-old male consumer from FR (weight: NA). The patient was diagnosed with: psoriasis and Daivobet was administered (dosage: NA) starting: Nov 02, 2012. The consumer developed a set of symptoms:
  • Pyrexia
  • Dermatitis Exfoliative
Other drugs used simultaneously:
  • Buspirone Hydrochloride
  • Anti-interleukine 17 (monoclonal Antibodies)
  • Amg 827 (monoclonal Antibodies)
  • Brodalumab (monoclonal Antibodies)
  • Antihypertensives (antihypertensives)
The patient was hospitalized.Those unexpected symptoms could be linked to a Daivobet treatment, however establishing a potential drug-safety problem requires a more detailed clinical analysis.

Leukopenia, Lymphopenia
This is a report of a possible correlation between Daivobet Ointment (daivobet) use and the following symptoms/side effect(s):
  • Leukopenia
  • Lymphopenia
which could contribute to an assessment of Daivobet Ointment (daivobet) risk profile.A 32-year-old male consumer from PL (weight: NA) was suffering from psoriasis and was treated with Daivobet Ointment (daivobet) (dosage: 1 ^finger Unit^) starting Oct 10, 2012.Other concurrent medications: NA.

Toxic Epidermal Necrolysis, Off Label Use
A 56-year-old male patient from PL (weight: NA) presented with the following symptoms: guttate psoriasis and after a treatment with Daivobet (dosage: About 2 Cm Of Ointment) experienced the following side effect(s):
  • Toxic Epidermal Necrolysis
  • Off Label Use
The treatment was started on NS. Daivobet was used in combination with the following drugs:
  • Clobetesolum (clobetasol)
This report could alert potential Daivobet consumers.

Osteochondrosis
In this report, a 27-year-old male patient from IE (weight: NA) was affected by a possible Daivobet side effect.The patient was diagnosed with psoriasis vulgaris. After a treatment with Daivobet (dosage: NA, start date: NS), the patient experienced the following side effect(s):
  • Osteochondrosis
The following simultaneously used drugs could have led to this reaction:
  • Mometasone (mometasone Furoate) (0.01 %, Cream)
  • Betamethasone Valerate (betamethasone Valerate) (0.1 %, Cream)
The findings here stress that side effects should be taken into consideration when evaluating a Daivobet treatment.

Staphylococcal Infection, Psoriasis, Off Label Use
This is a report of a 55-year-old patient from CH (weight: NA), who used Daivobet (dosage: NA) for a treatment of NA. After starting a treatment on NS, the patient experienced the following side effect(s):
  • Staphylococcal Infection
  • Psoriasis
  • Off Label Use
The following drugs could possibly have interacted with the Daivobet treatment NA.The patient was hospitalized.Taken together, these observations suggest that a Daivobet treatment could be related to side effect(s), such as Staphylococcal Infection, Psoriasis, Off Label Use.

Pneumonia
This pneumonia side effect was reported by a consumer or non-health professional from GB. A 56-year-old female patient (weight:NA) experienced the following symptoms/conditions: psoriasis. The patient was prescribed Daivobet (dosage: Topical), which was started on May 05, 2009. Concurrently used drugs: NA. When starting to take Daivobet the consumer reported the following symptoms:
  • Pneumonia
The patient was hospitalized. These side effects may potentially be related to Daivobet.

Cellulitis
This is a Daivobet Ointment (daivobet /01643401/) side effect report of a 56-year-old female patient (weight:NA) from UNITED STATES, suffering from the following symptoms/conditions: NA, who was treated with Daivobet Ointment (daivobet /01643401/) (dosage:Topical, start time: Jan 01, 2009), combined with:
  • Corticosteroids Not (corticosteroids Nos)
  • Enbrel
  • Remicade (Intravenous)
, and developed a serious reaction and a cellulitis side effect. The patient presented with:
  • Cellulitis
which developed after the beginning of treatment. The patient was hospitalized. This side effect report can indicate a possible existence of increased vulnerability to Daivobet Ointment (daivobet /01643401/) treatment in female patients suffering from NA, resulting in cellulitis.

Pruritus, Rash Macular, Burning Sensation
This report suggests a potential Daivobet Ointment (daivobet /01643401/) (oinment) pruritus side effect(s) that can have serious consequences. A 54-year-old female patient from UNITED STATES (weight:NA) was diagnosed with the following health condition(s): psoriasis and used Daivobet Ointment (daivobet /01643401/) (oinment) (dosage: Monday To Friday, Topical) starting Nov 07, 2011. Soon after starting Daivobet Ointment (daivobet /01643401/) (oinment) the patient began experiencing various side effects, including:
  • Pruritus
  • Rash Macular
  • Burning Sensation
Drugs used concurrently:
  • Prednisone Tab
  • Clobex Spray (clobetasol Propionate)
  • Cortisone Injection In Bursa (cortisone Acetate)
Although Daivobet Ointment (daivobet /01643401/) (oinment) demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as pruritus, may still occur.

Cushing's Syndrome, Overdose, Diabetes Mellitus, Myopathy, Condition Aggravated, Skin Ulcer, Tachycardia, Psoriasis
This cushing's syndrome problem was reported by a health professional from UNITED KINGDOM. A 49-year-old male patient (weight: NA) was diagnosed with the following medical condition(s): psoriasis.On NS a consumer started treatment with Daivobet Ointment (daivobet /01643401/) (ointment) (dosage: Topical). The following drugs/medications were being taken at the same time:
  • Diprosalic (betadermic) (ointment)
  • Doublebase (hydromol /00906601/) (gel)
  • Metformin Hcl
When commencing Daivobet Ointment (daivobet /01643401/) (ointment), the patient experienced the following unwanted symptoms /side effects:
  • Cushing's Syndrome
  • Overdose
  • Diabetes Mellitus
  • Myopathy
  • Condition Aggravated
  • Skin Ulcer
  • Tachycardia
  • Psoriasis
Although all drugs are carefully tested before they are licensed for use, they carry potential side effect risks. Some side effects, such as cushing's syndrome, may become evident only after a product is in use by the general population.

Abortion Induced
This is a Daivobetr side effect report of a 35-year-old female patient (weight: NA) from SPAIN. The patient developed the following symptoms/conditions: NA and was treated with Daivobetr (dosage: NA) starting Nov 16, 2010. Concurrently used drugs:
  • Humira
Soon after that, the consumer experienced the following of symptoms:
  • Abortion Induced
This opens a possibility that Daivobetr could cause abortion induced and that some female patients may be more susceptible.

Abortion Induced
A 35-year-old female patient (weight: NA) from SPAIN with the following symptoms: NA started Daivobetr treatment (dosage: NA) on Nov 16, 2010. Soon after starting Daivobetr treatment, the consumer experienced several side effects, including:
  • Abortion Induced
. Concurrently used drugs:
  • Humira
This finding indicates that some patients can be more vulnerable to developing Daivobetr side effects, such as abortion induced.

Pancreatic Carcinoma
This pancreatic carcinoma side effect was reported by a physician from SPAIN. A 68-year-old female patient (weight:NA) experienced the following symptoms/conditions: psoriasis.The patient was prescribed Daivobet (dosage: NA), which was started on Nov 04, 2009. Concurrently used drugs:
  • Clarelux (500 Ug/g)
  • Methotrexate
  • Humira
  • Clarelux
.When starting to take Daivobet the consumer reported symptoms, such as:
  • Pancreatic Carcinoma
These side effects may potentially be related to Daivobet. The patient was hospitalized.

Pancreatic Carcinoma
This is a report of a 68-year-old female patient (weight: NA) from SPAIN, suffering from the following symptoms/conditions: psoriasis, who was treated with Daivobet (dosage: NA, start time: Oct 19, 2009), combined with: NA. and developed a serious reaction and side effect(s). The consumer presented with:
  • Pancreatic Carcinoma
which developed after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Daivobet treatment in female patients, resulting in pancreatic carcinoma side effect.

Hyperhidrosis, Abasia, Erythema, Fatigue, Dyspnoea, Bone Pain, Abdominal Pain Upper, Skin Discolouration
This report suggests a potential Daivobet Hyperhidrosis, Abasia, Erythema, Fatigue, Dyspnoea, Bone Pain, Abdominal Pain Upper, Skin Discolouration side effect(s) that can have serious consequences. A female patient (weight: NA) from BRAZIL was diagnosed with the following symptoms/conditions: pustular psoriasis,polyarthritis and used Daivobet (dosage: Route: Topic. Dose: (50 Mcg+0.5mg)/g) starting Jan 07, 2011. Soon after starting Daivobet the patient began experiencing various side effects, including:
  • Hyperhidrosis
  • Abasia
  • Erythema
  • Fatigue
  • Dyspnoea
  • Bone Pain
  • Abdominal Pain Upper
  • Skin Discolouration
Drugs used concurrently:
  • Tocilizumab (Route: Endovenous; Form: Infusion)
  • Arava
  • Rituximab (Form: Infusion)
  • Omeprazole
  • Remicade
  • Prednisone
  • Allegra
  • Os-cal + D
Although Daivobet demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as hyperhidrosis, may still occur.

Lymphopenia, Pulmonary Haemorrhage, Traumatic Lung Injury, Psoriasis, Accident
This Lymphopenia, Pulmonary Haemorrhage, Traumatic Lung Injury, Psoriasis, Accident problem was reported by a physician from GERMANY. A 26-year-old male patient (weight: NA) was diagnosed with the following symptoms/conditions: psoriasis. On Feb 16, 2011 this consumer started treatment with Daivobet /01643401/ (dosage: Unk). The following drugs were being taken at the same time:
  • Ecural
  • Enbrel (50 Mg, 2x/week)
  • Advantan (Unk)
  • Enbrel (50 Mg, Weekly)
  • Enbrel (25 Mg, 2x/week)
When commencing Daivobet /01643401/, the patient experienced the following unwanted symptoms/side effects:
  • Lymphopenia
  • Pulmonary Haemorrhage
  • Traumatic Lung Injury
  • Psoriasis
  • Accident
Although all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as lymphopenia, may become evident only after a product is in use by the general population.

Hepatic Enzyme Abnormal, Skin Disorder
This is a report of a 38-year-old male patient (weight: NA) from SWITZERLAND. The patient developed the following symptoms/conditions: psoriatic arthropathy and was treated with Daivobet (dosage: NA) starting Nov 23, 2010. Concurrently used drugs:
  • Humira
  • Methotrexate
  • Arava
  • Methotrexate
Soon after that, the consumer experienced the following side effects:
  • Hepatic Enzyme Abnormal
  • Skin Disorder
This opens a possibility that Daivobet treatment could cause the above reactions, including hepatic enzyme abnormal, and some male subjects may be more susceptible.

Nausea, Arthralgia, Bone Pain, Erythema, Hyperhidrosis, Muscle Rigidity, Joint Range Of Motion Decreased, Arthropathy, Hypoaesthesia
A female patient (weight: NA) from BRAZIL with the following symptoms/conditions: pustular psoriasis started Daivobet treatment (dosage: Route: Topic. Dose: (50 Mcg+0.5mg)/g) on Jan 07, 2011. Soon after starting Daivobet treatment, the subject experienced various side effects, including:
  • Nausea
  • Arthralgia
  • Bone Pain
  • Erythema
  • Hyperhidrosis
  • Muscle Rigidity
  • Joint Range Of Motion Decreased
  • Arthropathy
  • Hypoaesthesia
Concurrently used drugs:
  • Omeprazole
  • Arava
  • Tocilizumab (Route: Endovenous; Form: Infusion)
  • Rituximab (Form: Infusion)
  • Remicade
  • Prednisone
  • Os-cal + D
  • Allegra
This finding indicates that some female patients could be more vulnerable to Daivobet.

1 of 2 



Keep Track of Side Effects

Note Your Observations

It is really important to keep of your symptoms, right from the time you start a new medicine. You can do it any way you prefer: in a notebook, in a computer file or using our online tool. You should also note down any other medicines you are taking at the same time, because there could be an interaction between these medicines.

Why Your Notes are Important

Your notes could be helpful in several ways:

  • You can use them to remind you of details that may alert your health care professional(s) to a problem
  • You will have a record to refer to in the future, in case you are ever prescribed the same medicine again

  • Log Form

    You can use the following log form to write down important information, like the date and time you experienced a side effect and your symptoms, how strong the symptoms were, and any other medicines you were using.

    Medicine Name and Dosage:
    Side Effects Scale Date & Time Other Medicine(s) or Treatment(s)
    Scale: 1 = very mild to 10 = very bad

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


    Discuss Daivobet Side Effects

    Did You Have a Daivobet Side Effect?

    Yes, Severe
    Yes, Moderate
    Yes, Minor
    No

    How Effective is Daivobet for You?

    Exceeded Expectations
    Effective
    Somewhat Effective
    Not Effective

    Daivobet Safety Alerts, Active Ingredients, Usage Information

    More About Daivobet

    Side Effects reported to FDA: 47

    Daivobet safety alerts: No

    Reported deaths: 2

    Reported hospitalizations: 13

    Latest Daivobet clinical trials